Troglitazone activates p21(Cip/WAF1) through the ERK pathway in HCT15 human colorectal cancer cells

Cited 28 time in webofscience Cited 29 time in scopus
  • Hit : 392
  • Download : 0
DC FieldValueLanguage
dc.contributor.authorKim, JAko
dc.contributor.authorPark, KSko
dc.contributor.authorKim, Hailko
dc.contributor.authorOh, SYko
dc.contributor.authorAhn, Yko
dc.contributor.authorOh, JWko
dc.contributor.authorChoi, KYko
dc.date.accessioned2013-03-06T04:05:35Z-
dc.date.available2013-03-06T04:05:35Z-
dc.date.created2012-02-06-
dc.date.created2012-02-06-
dc.date.issued2002-05-
dc.identifier.citationCANCER LETTERS, v.179, no.2, pp.185 - 195-
dc.identifier.issn0304-3835-
dc.identifier.urihttp://hdl.handle.net/10203/85755-
dc.description.abstractIn this study, we identified a new mechanism for the anti-proliferation of HCT15 colorectal cancer cells by troglitazone (TRO). Treating HCT15 cells with 20 muM of TRO transiently increased extracellular signal regulated kinase (ERK) activity within 15 min, and this subsequently induced p21(Cip/WAF1) cell cycle regulator and localized in the nucleus. Raf-1 modification and MEK activation also occurred after TRO treatment, and Elk-l-dependent trans-reporter gene expression was concomitantly induced. The induction and nuclear localization of p21(Cip/WAF1) by TRO were blocked by PD98059 pre-treatment, which suggested a role for the ERK pathway in p21(Cip/WAF1) activation. TRO inhibited BrdU incorporation and no BrdU incorporation was observed in most p21(Cip/WAF1)-activated cells. Therefore, TRO regulates the proliferation of HCT15 cells at least partly by a mechanism involving the activation of p21(Cip/WAF1). (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER SCI IRELAND LTD-
dc.subjectCOLON-CANCER-
dc.subjectINSULIN-RESISTANCE-
dc.subjectSIGNALING PATHWAY-
dc.subjectRECEPTOR-GAMMA-
dc.subjectCYCLE ARREST-
dc.subjectGROWTH-
dc.subjectTHIAZOLIDINEDIONES-
dc.subjectP21(WAF1/CIP1)-
dc.subjectINHIBITOR-
dc.subjectP21(CIP1)-
dc.titleTroglitazone activates p21(Cip/WAF1) through the ERK pathway in HCT15 human colorectal cancer cells-
dc.typeArticle-
dc.identifier.wosid000175320300009-
dc.identifier.scopusid2-s2.0-0037188311-
dc.type.rimsART-
dc.citation.volume179-
dc.citation.issue2-
dc.citation.beginningpage185-
dc.citation.endingpage195-
dc.citation.publicationnameCANCER LETTERS-
dc.identifier.doi10.1016/S0304-3835(01)00869-2-
dc.contributor.localauthorKim, Hail-
dc.contributor.nonIdAuthorKim, JA-
dc.contributor.nonIdAuthorPark, KS-
dc.contributor.nonIdAuthorOh, SY-
dc.contributor.nonIdAuthorAhn, Y-
dc.contributor.nonIdAuthorOh, JW-
dc.contributor.nonIdAuthorChoi, KY-
dc.type.journalArticleArticle-
dc.subject.keywordAuthortroglitazone-
dc.subject.keywordAuthorERK-
dc.subject.keywordAuthorp21(Cip/WAF1)-
dc.subject.keywordAuthorcell cycle-
dc.subject.keywordAuthoranti-cancer-
dc.subject.keywordPlusCOLON-CANCER-
dc.subject.keywordPlusINSULIN-RESISTANCE-
dc.subject.keywordPlusSIGNALING PATHWAY-
dc.subject.keywordPlusRECEPTOR-GAMMA-
dc.subject.keywordPlusCYCLE ARREST-
dc.subject.keywordPlusGROWTH-
dc.subject.keywordPlusTHIAZOLIDINEDIONES-
dc.subject.keywordPlusP21(WAF1/CIP1)-
dc.subject.keywordPlusINHIBITOR-
dc.subject.keywordPlusP21(CIP1)-
Appears in Collection
MSE-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 28 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0